Drug-coated balloon in patients with in-stent restenosis: A prospective observational study.

Aim: The aim of this study was to compare the safety and efficacy of paclitaxel-coated balloons (PCB) and sirolimus-coated balloons (SCB) in patients with in-stent restenosis (ISR).

Methods: This prospective, observational, single-centre pilot study enrolled 85 patients diagnosed with drug-eluting stent ISR. For all the eligible patients, various clinical baseline characteristics were collected, and angiography was performed to evaluate the lesion characteristics.

Nano-crush technique in narrow-angle (<70°) bifurcation: bench test, CT reconstruction, fluid dynamics, and clinical outcomes.

Background: Bifurcation stenting techniques are still refining and under testing. Nano-crush is a novel technique which allow minimum protrusion of side branch struts at the ostium. To demonstrate the efficacy of Nano-crush technique in narrow-angle bifurcation (<70°) using bench test model, 3D reconstruction of the stent structure, computational fluid dynamics study and a clinical follow-up.

Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India.

Introduction: Atorvastatin-80mg/day and Rosuvastatin-40mg/day are the commonest high-dose statin (3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors) regimes for post-PCI (Percutaneous Coronary Interventions) patients to lower (by ≥50%) blood low-density-lipoprotein cholesterol (LDL-C). Dearth of conclusive evidence from developing world, regarding overall safety, tolerability and comparative effectiveness (outcome/safety/tolerability/endothelial inflammation control) of Rosuvastatin over Atorvastatin in high-dose, given its higher cost, called for an overall and comparative assessment among post-PCI patients in a tertiary cardiac-care hospital of Kolkata, India.

Methods: A record-based non-concurrent cohort study was conducted involving 942 post-PCI patients, aged 18-75 years, on high-dose statin for three months and followed up for ≥one year.